CN117362275A - Tyrosine protein kinase inhibitor and application thereof - Google Patents
Tyrosine protein kinase inhibitor and application thereof Download PDFInfo
- Publication number
- CN117362275A CN117362275A CN202210751111.0A CN202210751111A CN117362275A CN 117362275 A CN117362275 A CN 117362275A CN 202210751111 A CN202210751111 A CN 202210751111A CN 117362275 A CN117362275 A CN 117362275A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkylene
- protein kinase
- alkyl
- tyrosine protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 52
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims abstract description 33
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 230000005856 abnormality Effects 0.000 claims abstract description 8
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 30
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 28
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 22
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 22
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims description 18
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 9
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 239000011630 iodine Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 5
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 29
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 24
- -1 but not limited to Chemical class 0.000 description 23
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 20
- 238000001308 synthesis method Methods 0.000 description 18
- WPJGHIVGAOVUAT-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyridine-3-carboxylic acid Chemical compound O=C1C(C(=O)O)=CC=CN1C1=CC=C(F)C=C1 WPJGHIVGAOVUAT-UHFFFAOYSA-N 0.000 description 16
- 239000002994 raw material Substances 0.000 description 16
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 15
- QAWFLJGZSZIZHO-UHFFFAOYSA-N methyl 4-bromobutanoate Chemical compound COC(=O)CCCBr QAWFLJGZSZIZHO-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 12
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ZXNZHVDQMZJUKH-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyridine-3-carboxamide Chemical compound O=C1C(C(=O)N)=CC=CN1C1=CC=C(F)C=C1 ZXNZHVDQMZJUKH-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 8
- KYLVAMSNNZMHSX-UHFFFAOYSA-N methyl 6-bromohexanoate Chemical group COC(=O)CCCCCBr KYLVAMSNNZMHSX-UHFFFAOYSA-N 0.000 description 8
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- JCNHPLIJZGORQU-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopiperidine-3-carboxylic acid Chemical compound O=C1C(C(=O)O)CCCN1C1=CC=C(F)C=C1 JCNHPLIJZGORQU-UHFFFAOYSA-N 0.000 description 6
- QVOSINVMLQMWPO-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound FC1=CC=C(C=C1)N1C(C(CC1)C(=O)N)=O QVOSINVMLQMWPO-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- WNXNUPJZWYOKMW-UHFFFAOYSA-M 5-bromopentanoate Chemical compound [O-]C(=O)CCCCBr WNXNUPJZWYOKMW-UHFFFAOYSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001613 neoplastic effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- GKKWONDBUXUCHF-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1C(C(=O)O)CCN1C1=CC=C(F)C=C1 GKKWONDBUXUCHF-UHFFFAOYSA-N 0.000 description 3
- KIXWRXJXMVUWCP-UHFFFAOYSA-N 2-oxo-1-phenylpyrrolidine-3-carboxylic acid Chemical compound O=C1C(C(=O)O)CCN1C1=CC=CC=C1 KIXWRXJXMVUWCP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 101100154895 Oryzias latipes tyr gene Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091005729 TAM receptors Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- ZCQHXCZWPBJLKD-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-phenylmethoxyquinoline Chemical compound C1=CN=C2C=C(OCC=3C=CC=CC=3)C(OC)=CC2=C1OC1=CC=C([N+]([O-])=O)C=C1F ZCQHXCZWPBJLKD-UHFFFAOYSA-N 0.000 description 2
- OTFCCVPKOQIVNF-UHFFFAOYSA-N 4-(2-fluoro-4-nitrophenoxy)-6-methoxyquinolin-7-ol Chemical compound C1=CN=C2C=C(O)C(OC)=CC2=C1OC1=CC=C([N+]([O-])=O)C=C1F OTFCCVPKOQIVNF-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101150022345 GAS6 gene Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- RAVVJKCSZXAIQP-UHFFFAOYSA-N methyl 5-bromopentanoate Chemical group COC(=O)CCCCBr RAVVJKCSZXAIQP-UHFFFAOYSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 108091006024 signal transducing proteins Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SYKLZPMKNBDEOF-UHFFFAOYSA-N 4-chloro-6-methoxy-7-phenylmethoxyquinoline Chemical compound COC1=CC2=C(Cl)C=CN=C2C=C1OCC1=CC=CC=C1 SYKLZPMKNBDEOF-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 101150082854 Mertk gene Proteins 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102100029293 Tubby-related protein 1 Human genes 0.000 description 1
- 101710147826 Tubby-related protein 1 Proteins 0.000 description 1
- 101150098329 Tyro3 gene Proteins 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compounds useful as tyrosine protein kinase inhibitors are disclosed which inhibit AXL, KDR and/or CSF-1R kinase. The invention also discloses application of the compound in preparing medicines for treating tumors and related diseases caused by the abnormality of AXL, KDR and/or CSF-1R.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a tyrosine protein kinase inhibitor, in particular to a compound for inhibiting AXL, KDR and CSF-1R kinase; also relates to the application of the inhibitor in medicaments for treating tumors and related diseases caused by abnormal AXL, KDR and CSF-1R kinase.
Background
Protein tyrosine kinases (protein tyrosine kinase, PTKs) are key kinases that catalyze the transfer of gamma phosphate groups of ATP to protein substrate tyrosine, and transduce extracellular signals into cells by phosphorylating tyrosine on the receptor itself and downstream signaling proteins, thus PTKs are important components of cellular signaling pathways. PTKs activate numerous signaling pathways within cells, leading to changes in cell proliferation, differentiation, migration, and metabolism.
Development of the vascular system is dependent on the synergistic effect of the PTK subfamily and its cognate ligands. Angiogenesis requires Vascular Endothelial Growth Factor (VEGF) and the receptor KDR acting in concert therewith. KDR is a key signaling protein involved in angiogenesis. Autophosphorylation of KDR, a key protein tyrosine kinase involved in cellular signal transduction processes, represents a key step in promoting angiogenesis.
Axl belongs to the TAM receptor tyrosine kinase family, which also contains the Tyro3, mer (TAM) subfamily. Ligands that activate the TAM receptor are growth retardation-specific gene 6 (Gas 6), protein S, tubby and tubby-like protein 1 (tubp 1). Gas6 has a sub-nanomolar affinity for Axl and is the only ligand that activates Axl; the binding affinity of Tyro, mer to Gas6 is reduced, while protein S preferentially binds to Tyro and Mer. TAM receptors have been demonstrated to be overexpressed in many solid tumors, such as breast, lung, brain, and gut tumors, etc., as detected by high Axl expression in acute leukemia patients; axl induces tumor cell proliferation and survival, and induces tolerance to apoptosis and chemotherapeutic drugs; furthermore, axl also plays a role in mediating cancer cell migration and invasion.
CSF-1R (colly-stimulating factor-1, CSF-1R) is the first hematopoietic growth factor isolated as a pure protein and acts through the colony growth factor receptor CSF-1R (CSF-1 receptor) of myeloid progenitor cells. Inhibition of CSF-1R may enhance the anti-tumor effects of other PTK inhibitors by enhancing tumor immune escape, and studying the combined inhibition of CSF-1/CSF-1R and related signaling pathways is a novel strategy for tumor therapy.
Although single-target PTK inhibitors show respective biological activity and anti-tumor effect through unique targets, more and more clinical results show that the curative effect is still limited, so that the development of new PTK multi-target combined application inhibitors can have unique and potential superiority for treating tumors.
Disclosure of Invention
In order to solve the technical problems, the invention provides a novel tyrosine protein kinase inhibitor which can inhibit kinase activity and tumor cell proliferation in vitro and can show excellent anti-tumor activity in animal models.
In a first aspect, the present invention provides a compound of formula (I), an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated product thereof:
wherein,
R 1 is C 1 -C 6 Alkyl, R 2 Is that(D is an isotope of hydrogen); or R is 2 Is C 1 -C 6 Alkyl, R 1 Is->(D is an isotope of hydrogen);
y is selected from C 1 -C 10 Alkylene, C 1 -C 10 Alkylene amino group, C 1 -C 10 Alkylene oxide, C 1 -C 10 Halogenated alkylene, piperidylene, C 1 -C 10 Alkylene piperidinyl, piperazinyl or C 1 -C 10 An alkylene piperazinyl group;
G 1 and G 2 Are independently selected from hydrogen, deuterium, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 An alkoxy group;
w is selected from the following groups:
in some preferred embodiments of the invention, in formula (I), R 1 Is C 1 -C 3 Alkyl, R 2 Is that Or R is 2 Is C 1 -C 3 Alkyl, R 1 Is->
Y is selected from C 3 -C 6 Alkylene, C 3 -C 6 Alkylene amino group, C 3 -C 6 Alkylene oxide, C 3 -C 6 A halogenated alkylene group.
In some preferred embodiments of the invention, in formula (I), R 1 Is C 1 -C 3 Alkyl, R 2 Is that Y is selected from C 3 -C 5 Alkylene or C 3 -C 5 A halogenated alkylene group.
In some preferred embodiments of the invention, in formula (I), G 1 And G 2 Each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine or iodine.
In some preferred embodiments of the invention, in formula (I), W is selected from the following groups:
in some preferred embodiments of the invention, the invention also provides compounds including, but not limited to, the following:
in a second aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof, and a pharmaceutically acceptable excipient.
In some preferred embodiments of the invention, the compounds of the invention (including racemates, enantiomers, stereoisomers, deuterides) or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, and pharmaceutically acceptable carriers or excipients thereof are prepared into pharmaceutical compositions useful for administration.
The route of administration of the pharmaceutical composition of the invention may be: (1) oral administration: such as tablets, capsules, etc.; (2) injection: such as intravenous injection, subcutaneous injection, intramuscular injection, eyeball injection, etc.; (3) intrarectal: such as suppositories, gels, and the like; (4) nostril inhalation: such as sprays, aerosols, and the like; (5) The drug is administrated by a drug release system such as liposome, a slow release technology, a controlled release technology and the like.
The term "pharmaceutically acceptable salt" refers to salts that maintain the biological activity possessed by the compounds of the invention without exhibiting undesirable toxicological effects. Illustrative examples thereof include, but are not limited to, acid addition salts with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, hydrobromic acid, and the like, and salts with organic acids such as acetic acid, malic acid, tartaric acid, oxalic acid, succinic acid, benzoic acid, tannic acid, alginic acid, polyglutamic acid, and the like; the compounds of the present invention may also be administered as pharmaceutically acceptable quaternary ammonium salts.
In a third aspect, the present invention provides the use of said compound, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated product thereof or said pharmaceutical composition for the manufacture of a medicament for the prevention or treatment of a disease caused by an abnormality of tyrosine protein kinase.
Preferably, the tyrosine protein kinase is selected from one or more of receptor tyrosine kinase (AXL), vascular endothelial growth factor receptor 2 (KDR) and colony stimulating factor-1receptor (CSF-1R).
Preferably, the disease caused by tyrosine protein kinase abnormality includes neoplastic diseases such as solid tumors, such as gastric cancer, lung cancer, breast cancer, hematological tumors such as leukemia; and non-neoplastic diseases, such as inflammatory diseases, autoimmune diseases.
In a fourth aspect, the invention provides the use of said compound, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof or said pharmaceutical composition in the manufacture of a medicament for inhibiting tyrosine protein kinase.
Preferably, the tyrosine protein kinase is selected from one or more of receptor tyrosine kinase (AXL), vascular endothelial growth factor receptor 2 (KDR) and colony stimulating factor-1receptor (CSF-1R).
In a fifth aspect, the present invention provides a method for preventing or treating a disease caused by abnormal tyrosine protein kinase, comprising administering to a subject in need thereof an effective amount of the compound of the present invention, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof or the pharmaceutical composition.
Preferably, the tyrosine protein kinase is selected from one or more of receptor tyrosine kinase (AXL), vascular endothelial growth factor receptor 2 (KDR) and colony stimulating factor-1receptor (CSF-1R).
Preferably, the disease caused by tyrosine protein kinase abnormality includes neoplastic diseases such as solid tumors, such as gastric cancer, lung cancer, breast cancer, hematological tumors such as leukemia; and non-neoplastic diseases, such as inflammatory diseases, autoimmune diseases.
The tyrosine protein kinase inhibitor provided by the invention can inhibit kinase activity and tumor cell proliferation in vitro and has excellent anti-tumor activity in animal models, so that the tyrosine protein kinase inhibitor can be used as a novel PTK multi-target combined inhibitor and has unique and potential superiority for treating tumors.
Drawings
FIG. 1 shows the antitumor effect of the compounds of the examples on human leukemia MOLM-13 cell nude mice transplantation tumors.
Figure 2 shows the body weight change before and after administration of tumor-transplanted nude mice.
Detailed Description
The following examples are intended to further illustrate the invention and are not intended to limit the scope of the invention.
Definition of the definition
The terms and techniques used herein have the same meaning as understood by those skilled in the art.
The term "AXL" refers to a receptor tyrosine kinase in the TAM (Tyro 3, AXL, merTK) family.
The term "KDR" refers to vascular endothelial growth factor receptor 2 (VEGFR 2).
The term "CSF-1R" refers to colony stimulating factor-1receptor (CSF-1R).
The term "alkyl" refers to straight and branched chain aliphatic groups containing 1,2, 3, 4, 5, 6, 7, 8, 9, 10 carbon atoms, and optionally substituted with one or more substituents; alkyl groups as defined include, but are not limited to, methyl, substituted methyl, ethyl, substituted ethyl, propyl, substituted propyl, isopropyl, substituted isopropyl, butyl, substituted butyl, isobutyl, substituted isobutyl, pentyl, substituted pentyl, hexyl, substituted hexyl, and the like.
The term "alkylene" refers to the-CH located between and linking two chemical groups 2 -a group; exemplary alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, and the like.
The term "haloalkyl" refers to an alkyl chain in which one or more hydrogens are replaced with a halogen.
The term "halogen" includes fluorine, chlorine, bromine and iodine.
The term "alkoxy" refers to-O alkyl groups, e.g., O-C 1 -C 6 An alkyl group.
The term "cycloalkyl" refers to saturated or partially saturated cyclic groups having 3, 4, 5, 6 carbon compositions, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
The term "heteroaryl" refers to a monocyclic or bicyclic group consisting of 5, 6, 7, 8, 9, 10 ring atoms; among the atoms constituting the ring, 1 or more hetero atoms selected from N, O and S, for example, 1,2, 3, 4, 5, 6, 7, 8, 9 are contained in addition to the carbon atoms.
The term "aralkyl" refers to an aryl group attached to an alkyl group, which may be independently optionally substituted.
The term "heteroalkyl" refers to an alkyl group in which one or more, for example 1,2, 3, 4, 5 carbon atoms in the alkyl group are replaced with O, S or N atoms.
The term "aryl" refers to a group consisting of 1,2, 3 aromatic rings, optionally substituted; the aryl groups include, but are not limited to, phenyl, naphthyl, and the like.
The term "heterocyclyl" refers to a group of a 3, 4, 5, 6, 7, 8, 9, 10 membered ring containing one or more (e.g., 1,2, 3, 4, 5, 6, 7, 8, 9) nitrogen, oxygen or sulfur atoms in addition to carbon atoms in the ring-forming atom, which may be monocyclic, bicyclic, spiro or bridged; the term "heterocyclylalkyl" refers to a group that is attached to the remainder of the molecule through an alkyl group attached to a heterocyclyl.
Compounds of formula (I)
The present invention provides a compound represented by the general formula (I):
wherein,
R 1 is C 1 -C 6 Alkyl, R 2 Is that(D is an isotope of hydrogen); or R is 2 Is C 1 -C 6 Alkyl, R 1 Is->(D is an isotope of hydrogen);
y is selected from C 1 -C 10 Alkylene, C 1 -C 10 Alkylene amino group, C 1 -C 10 Alkylene oxide, C 1 -C 10 Halogenated alkylene, piperidylene, C 1 -C 10 Alkylene piperidinyl, piperazinyl or C 1 -C 10 An alkylene piperazinyl group;
G 1 and G 2 Are independently selected from hydrogen, deuterium, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 An alkoxy group;
w is selected from the following groups:
in some preferred embodiments of the invention, in formula (I), R 1 Is C 1 -C 3 Alkyl, R 2 Is that Or R is 2 Is C 1 -C 3 Alkyl, R 1 Is->
Y is selected from C 3 -C 6 Alkylene, C 3 -C 6 Alkylene amino group, C 3 -C 6 Alkylene oxide, C 3 -C 6 A halogenated alkylene group.
In some preferred embodiments of the invention, in formula (I), R 1 Is C 1 -C 3 Alkyl, R 2 Is that Y is selected from C 3 -C 5 Alkylene or C 3 -C 5 A halogenated alkylene group.
In some preferred embodiments of the invention, in formula (I), G 1 And G 2 Each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine or iodine.
In some preferred embodiments of the invention, in formula (I), W is selected from the following groups:
the present invention also provides compounds including, but not limited to, the following:
examples and embodiments
The embodiments and examples are intended to be illustrative of the practice of the invention in detail and are not intended to limit the scope of the invention. The compounds described in this invention may be prepared by a variety of methods known to those skilled in the art, including but not limited to the methods employed in this example and other alternatives. On the premise of the design thought of the invention, the modification or replacement of the technical scheme of the invention belongs to the protection scope of the invention.
The compounds of the general formula (I) according to the invention can be synthesized by the process of the following general formula route:
the main synthetic reaction process is as follows:
step 1, taking a compound 2, namely 7- (benzyloxy) -4-chloro-6-alkoxyquinoline, as a starting material, and carrying out an ether formation reaction with a nitrophenol compound 3 in DIPEA to generate an intermediate 4;
step 2, hydrolyzing the intermediate 4 in hydrochloric acid to remove benzyl to generate an intermediate 5;
step 3, reacting the intermediate 5 with a bromomethyl ester compound 6 under an alkaline condition to generate an intermediate 7;
step 4, reducing amino on the nitro group of the intermediate 7 to generate an intermediate 8;
step 5, performing condensation reaction on the intermediate 8 and the carboxylic acid compound 9 to generate an amide intermediate 10;
step 6, the intermediate 10 undergoes hydrolysis reaction to produce the final product I.
Example 1.4- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butanoic acid
Step 1:
n, N-diisopropylethylamine (6.25 mL,35.86mmol,2.15 eq) was added to a mixture of 7-benzyloxy-4-chloro-6-methoxyquinoline (5.00 g,16.68mmol,1.00 eq) and 2-fluoro-4-nitrophenol (3.67 g,23.35mmol,1.40 eq) in chlorobenzene (25 mL). Oil bath at 140 ℃ and reflux overnight. The reaction was completed. Cooled to room temperature. 1M aqueous sodium hydroxide (50 mL) was added to precipitate a solid. And (5) decompressing and filtering, and leaching the filter cake with water for three times to obtain a yellow-green filter cake. The filter cake was stirred with ethanol four times to give 7- (benzyloxy) -4- (2-fluoro-4-nitrophenoxy) -6-methoxyquinoline (4.52 g,64.46%, brown solid).
Step 2:
7- (benzyloxy) -4- (2-fluoro-4-nitrophenoxy) -6-methoxyquinoline (5.80 g,13.80 mmol) and 6M aqueous hydrochloric acid (60 mL) were mixed and the reaction was completed under reflux at 120℃for two hours. Cooled to room temperature. The reaction solution was diluted with water. Filtering under reduced pressure, washing the filter cake with water for three times, and drying. 4- (2-fluoro-4-nitrophenoxy) -6-methoxyquinolin-7-ol (3.70 g,81.20% gray solid) was obtained.
Step 3:
potassium carbonate (1.85 g,13.35mmol,3.00 eq) and methyl 4-bromobutyrate (1.61 g,8.90mmol,2.00 eq) were added to a solution of 4- (2-fluoro-4-nitrophenoxy) -6-methoxyquinolin-7-ol (1.47 g,4.45mmol,1.00 eq) in N, N-dimethylformamide (15 mL) and reacted in an oil bath at 90℃for four and half hours. The reaction was completed and cooled to room temperature. The reaction solution was poured into water to precipitate a large amount of solids. And (5) decompressing and filtering, leaching the filter cake for three times, and drying. Methyl 4- ((4- (2-fluoro-4-nitrophenoxy) -6-methoxyquinolin-7-yl) oxy) butyrate (1.43 g, yield 74.9% as yellow solid) was obtained.
Step 4:
methyl 4- ((4- (2-fluoro-4-nitrophenoxy) -6-methoxyquinolin-7-yl) oxy) butyrate (2.65 g,6.22mmol,1.00 eq), ammonium formate (1.18 g,18.65mmol,3.00 eq), 10% palladium on carbon (992.37 mg) and methanol (30 mL) were mixed. The reaction was carried out at room temperature (27 ℃ C.) for four hours. The reaction was completed. The mixture was filtered through celite and concentrated under reduced pressure to give a brown solid. After dissolution of ethyl acetate, the mixture was washed three times with water and twice with saturated sodium chloride. Dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. And (5) drying. Methyl 4- ((4- (4-amino-2-fluorophenoxy) -6-methoxyquinolin-7-yl) oxy) butyrate (2.05 g, 82.2% yield) was obtained as a brown solid.
Step 5:
methyl 4- ((4- (4-amino-2-fluorophenoxy) -6-methoxyquinolin-7-yl) oxy) butyrate (0.93 g,2.33mmol,1.00 eq), 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid (816.41 mg,3.50mmol,1.50 eq), 2- (7-azobenzotriazole) -N, N, N ', N' -tetramethylurea hexafluorophosphate (1.77 g,4.67mmol,2.00 eq), 4-dimethylaminopyridine (142.57 mg,1.17mmol,0.50 eq) and N, N-diisopropylethylamine (1.63 mL,9.34mmol,4.00 eq) were dissolved in N, N-dimethylformamide (10 mL). The reaction was carried out at room temperature (20 ℃ C.) overnight. The reaction was completed. The reaction solution was poured into water to precipitate a solid, which was filtered under reduced pressure. The filter cake was washed three times with water. Column chromatography purification (DCM: meoh=30:1) afforded methyl 4- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butyrate (1.19 g, yield 81.9% brown solid).
Step 6:
methyl 4- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butyrate (521 mg, 847.1. Mu. Mol,1.00 eq) was dissolved in tetrahydrofuran (5 mL). A solution of lithium hydroxide monohydrate (142.12 mg,3.39mmol,4.00 eq) in water (5 mL) was added. The reaction was carried out at room temperature for one hour. The reaction was completed. The reaction solution was diluted with water, and the pH was adjusted to about 1 with 4M aqueous hydrochloric acid to precipitate a gum, which was filtered. Column chromatography (DCM: meoh=20:1) was purified and concentrated under reduced pressure. Stirring and washing with dichloromethane and tetrahydrofuran successively, and filtering to obtain white filter cake. Oven drying to give 4- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butyric acid (332.9 mg, yield 65.4% as white solid).
1 H NMR(400MHz,DMSO)δ12.20(s,1H),8.80(d,J=6.2Hz,1H),8.60(d,J=7.1Hz,1H),8.24(t,J=8.8Hz,2H),7.68(s,2H),7.60-7.54(m,4H),7.32(t,J=6.8Hz,2H),6.80(d,J=7.1Hz,1H),6.72(t,J=7.1Hz,1H),4.15(t,J=6.2Hz,2H),3.90(s,3H),3.64–3.56(m,1H),2.21(t,J=7.1Hz,2H),1.62–1.50(m,2H)MS:m/z(ESI+)602.7[M+H] + 。
Example 2.5- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 2 was carried out according to the synthesis method of example 1, and in step 3, methyl 4-bromobutyrate was replaced with methyl 5-bromovalerate as an intermediate material.
1 H NMR(400MHz,DMSO)δ12.16(s,1H),8.74(d,J=6.8Hz,1H),8.54(d,J=7.0Hz,1H),8.14(t,J=7.6Hz,2H),7.70(s,2H),7.68-7.59(m,4H),7.38(t,J=7.1Hz,2H),6.84(d,J=7.0Hz,1H),6.62(t,J=6.9Hz,1H),4.19(t,J=6.6Hz,2H),3.87(s,3H),3.60–3.52(m,1H),2.26(t,J=7.1Hz,2H),1.72–1.69(m,2H),1.62–1.54(m,2H)MS:m/z(ESI+)616.4[M+H] + 。
Example 3.6- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 3 was carried out according to the synthesis method of example 1, and in step 3, methyl 4-bromobutyrate was replaced with methyl 6-bromohexanoate as an intermediate material.
1 H NMR(400MHz,DMSO)δ12.19(s,1H),8.81(d,J=6.4Hz,1H),8.59(d,J=7.1Hz,1H),8.14(t,J=9.0Hz,2H),7.74(s,2H),7.632-7.561(m,4H),7.43(t,J=8.6Hz,2H),6.97(d,J=6.4Hz,1H),6.74(t,J=6.9Hz,1H),4.22(t,J=6.0Hz,2H),4.04(s,3H),3.65–3.55(m,1H),2.26(t,J=7.1Hz,2H),1.93–1.81(m,2H),1.66–1.56(m,2H),1.54–1.42(m,2H)。MS:m/z(ESI+)630.8[M+H] + 。
Example 4.4- ((4- (4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butanoic acid
The synthesis of example 4 was performed with reference to the synthesis method of example 1. In the step 1 reaction, the intermediate raw material 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol.
1 H NMR(400MHz,DMSO)δ12.19(s,1H),8.81(d,J=6.4Hz,1H),8.59(d,J=7.1Hz,1H),8.14(t,J=9.0Hz,2H),7.74(s,2H),7.632-7.561(m,4H),7.43(t,J=8.6Hz,2H),6.97(d,J=6.4Hz,1H),6.74(t,J=6.9Hz,1H),4.22(t,J=6.0Hz,2H),4.04(s,3H),3.65–3.55(m,1H),2.26(t,J=7.1Hz,2H),1.93–1.81(m,2H),1.66–1.56(m,2H),1.54–1.42(m,2H),MS:m/z(ESI+)583.57[M+H] + 。
Example 5.5- ((4- (4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 5 was performed with reference to the synthesis method of example 1. In the step 1 reaction, the intermediate raw material 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3 reaction, the intermediate raw material methyl 5-bromopentanoate is used for replacing methyl 4-bromobutyrate.
1 H NMR(400MHz,DMSO)δ11.89(s,1H),8.74(d,J=7.1Hz,1H),8.54(d,J=6.8Hz,1H),8.18(t,J=7.1Hz,2H),7.68(s,2H),7.58-7.42(m,4H),7.30(t,J=7.0Hz,2H),6.83(t,J=7.6Hz,2H),6.62(d,J=6.8Hz,1H),3.98(t,J=6.8Hz,2H),3.72(s,3H),3.48–3.32(m,1H),2.21(t,J=7.2Hz,2H),1.58–1.50(m,2H)1.48–1.40(m,2H)MS:m/z(ESI+)598.5[M+H] + 。
Example 6.6- ((4- (4- (1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 6 was performed with reference to the synthesis method of example 1. In the step 1 reaction, the intermediate raw material 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3 reaction, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-bromobutyrate.
1 H NMR(400MHz,DMSO)δ11.89(s,1H),8.74(d,J=7.1Hz,1H),8.54(d,J=6.8Hz,1H),8.18(t,J=7.1Hz,2H),7.68(s,2H),7.58-7.42(m,4H),7.30(t,J=7.0Hz,2H),6.83(t,J=7.6Hz,2H),6.62(d,J=6.8Hz,1H),3.98(t,J=6.8Hz,2H),3.72(s,3H),3.48–3.32(m,1H),2.21(t,J=7.2Hz,2H),1.58–1.50(m,2H)1.48–1.40(m,2H)MS:m/z(ESI+)611.63[M+H] + 。
Example 7.4- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxopiperidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butanoic acid
The synthesis of example 7 was performed with reference to the synthesis method of example 1. In step 5, the intermediate 1- (4-fluorophenyl) -2-oxopiperidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.17(s,1H),8.50(d,J=7.1Hz,1H),8.36(t,J=8.2Hz,2H),7.68(s,2H),7.60-7.54(m,3H),7.32(t,J=6.8Hz,2H),6.80(d,J=7.1Hz,1H),4.20(t,J=7.4Hz,2H),3.80(s,3H),3.72–3.42(m,5H),2.19(t,J=8.2Hz,2H),1.94–1.70(m,3H)1.60–1.52(m,2H)MS:m/z(ESI+)606.4[M+H] + 。
Example 8.5- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxopiperidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 8 was performed with reference to the synthesis method of example 1. In the step 3, the intermediate raw material of 5-bromovalerate is used for replacing 4-bromobutyric acid methyl ester; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopiperidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.22(s,1H),8.68(d,J=6.8Hz,1H),8.28(t,J=7.2Hz,2H),7.60(s,2H),7.70-7.58(m,3H),7.46(t,J=7.1Hz,2H),6.72(d,J=6.8Hz,1H),4.08(t,J=7.1Hz,2H),3.60(s,3H),3.52–3.36(m,5H),2.18(t,J=8.0Hz,2H),1.90–1.71(m,3H),1.70–1.62(m,2H)1.60–1.50(m,2H)1.42–1.36(m,2H)MS:m/z(ESI+)620.8[M+H] + 。
Example 9.6- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxopiperidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 9 was performed with reference to the synthesis method of example 1. In the step 3, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-bromobutyrate; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopiperidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.12(s,1H),8.54(d,J=7.2Hz,1H),8.18(t,J=6.8Hz,2H),7.66(s,2H),7.58-7.48(m,3H),7.38(t,J=6.8Hz,2H),6.64(d,J=6.8Hz,1H),4.02(t,J=9.1Hz,2H),3.60(s,3H),3.50–3.38(m,5H),2.20(t,J=8.0Hz,2H),2.06–1.81(m,3H),1.66–1.52(m,2H)1.48–1.30(m,2H)MS:m/z(ESI+)634.7[M+H] + 。
Example 10.4- ((4- (4- (1- (4-fluorophenyl) -2-oxopiperidin-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butanoic acid
The synthesis of example 10 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopiperidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.20(s,1H),8.52(d,J=7.1Hz,1H),8.36(t,J=6.8Hz,2H),7.68(s,2H),7.62-7.52(m,4H),7.30(t,J=7.1Hz,2H),6.80(d,J=6.8Hz,1H),4.18(t,J=7.2Hz,2H),3.76(s,3H),3.70–3.40(m,5H),2.20(t,J=9.0Hz,2H),1.94–1.70(m,3H)1.64–1.56(m,2H)MS:m/z(ESI+)588.6[M+H] + 。
Example 11.5- ((4- (4- (1- (4-fluorophenyl) -2-oxopiperidin-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 11 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3, the intermediate raw material of 5-bromovalerate is used for replacing 4-bromobutyric acid methyl ester; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopiperidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.26(s,1H),8.74(d,J=8.2Hz,1H),8.37(t,J=7.1Hz,2H),7.72(s,2H),7.66-7.48(m,4H),7.36(t,J=6.8Hz,2H),6.68(d,J=7.1Hz,1H),4.02(t,J=7.2Hz,2H),3.54(s,3H),3.48–3.42(m,5H),2.28(t,J=8.0Hz,2H),2.00–1.71(m,3H),1.66–1.60(m,2H)1.58–1.42(m,2H)MS:m/z(ESI+)602.5[M+H] + 。
Example 12.6- ((4- (4- (1- (4-fluorophenyl) -2-oxopiperidin-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 12 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-bromobutyrate; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopiperidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.26(s,1H),8.74(d,J=8.2Hz,1H),8.37(t,J=7.1Hz,2H),7.72(s,2H),7.66-7.48(m,4H),7.36(t,J=6.8Hz,2H),6.68(d,J=7.1Hz,1H),4.02(t,J=7.2Hz,2H),3.54(s,3H),3.48–3.42(m,5H),2.28(t,J=8.0Hz,2H),2.00–1.71(m,3H),1.66–1.60(m,2H)1.58–1.42(m,2H)MS:m/z(ESI+)615.66[M+H] + 。
Example 13.5- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-2, 5-dihydro-1H-pyrrole-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 13 was performed according to the method of example 1. In the step 3, the intermediate raw material of 5-bromovalerate is used for replacing 4-bromobutyric acid methyl ester; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxo-2, 5-dihydro-1H-pyrrole-3-carboxylic acid was used in place of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.17(s,1H),8.70(d,J=7.1Hz,1H),8.35(t,J=7.2Hz,2H),7.70(s,2H),7.64-7.52(m,3H),7.32(t,J=6.8Hz,2H),7.02(t,J=2.4Hz,1H)6.64(d,J=6.8Hz,1H),4.22(t,J=1.6Hz,2H),4.08(t,J=7.2Hz,2H),3.54(s,3H),3.50–3.36(m,5H),2.22(t,J=8.0Hz,2H),MS:m/z(ESI+)604.6[M+H] + 。
Example 14.6- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxo-2, 5-dihydro-1H-pyrrole-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 14 was performed with reference to the synthesis method of example 1. In the step 3, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-bromobutyrate; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxo-2, 5-dihydro-1H-pyrrole-3-carboxylic acid was used in place of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.21(s,1H),8.65(d,J=6.4Hz,1H),8.24(t,J=7.1Hz,2H),7.62(s,2H),7.56-7.46(m,3H),7.36(t,J=7.4Hz,2H),7.14(t,J=2.1Hz,1H)6.56(d,J=6.8Hz,1H),4.30(t,J=2.1Hz,2H),4.08(t,J=6.8Hz,2H),3.64(s,3H),3.52–3.34(m,5H),2.28(t,J=7.4Hz,2H),2.00–1.71(m,2H),MS:m/z(ESI+)618.6[M+H] + 。
Example 15.6- ((4- (4- (1- (4-fluorophenyl) -2-oxo-2, 5-dihydro-1H-pyrrole-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 15 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-bromobutyrate; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxo-2, 5-dihydro-1H-pyrrole-3-carboxylic acid was used in place of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.16(s,1H),8.70(d,J=7.1Hz,1H),8.45(t,J=6.6Hz,2H),7.80(s,2H),7.74-7.62(m,4H),7.30(t,J=7.1Hz,2H),7.12(t,J=2.1Hz,1H)6.70(d,J=7.8Hz,1H),4.22(t,J=2.2Hz,2H),4.13(t,J=9.0Hz,2H),3.60(s,3H),3.56–3.40(m,5H),2.22(t,J=7.4Hz,2H),1.82–1.68(m,2H),MS:m/z(ESI+)600.5[M+H] + 。
EXAMPLE 16.4- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butanoic acid
The synthesis of example 16 was performed with reference to the synthesis method of example 1. In step 5, the intermediate 1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.10(s,1H),8.63(d,J=7.4Hz,1H),8.40(t,J=6.8Hz,2H),7.50(s,2H),7.48-7.36(m,3H),7.24(t,J=7.1Hz,2H),7.12(d,J=4.2Hz,1H),4.30(t,J=2.1Hz,2H),4.20-4.12(m,2H),3.66(s,3H),3.58(t,J=1.7Hz,1H)3.56–3.32(m,3H),,2.10–1.81(m,2H),MS:m/z(ESI+)592.6[M+H] + 。
Example-17.5- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 17 was performed according to the method of example 1. In the step 3, the intermediate raw material of 5-bromovalerate is used for replacing 4-methyl butyrate; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ12.18(s,1H),8.70(d,J=7.1Hz,1H),8.53(t,J=7.1Hz,2H),7.54(s,2H),7.50-7.38(m,3H),7.22(t,J=7.2Hz,2H),7.16(d,J=3.6Hz,1H),4.34(t,J=2.1Hz,2H),4.28-4.16(m,2H),3.72(s,3H),3.64(t,J=1.7Hz,1H)3.60–3.38(m,3H),,2.08–1.80(m,2H),1.76–1.68(m,2H),MS:m/z(ESI+)606.7[M+H] + 。
EXAMPLE 18.6- ((4- (2-fluoro-4- (1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 18 was performed with reference to the synthesis method of example 1. In the step 3, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-butyrate; in step 5, the intermediate 1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ11.98(s,1H),8.64(d,J=7.2Hz,1H),8.57(t,J=6.8Hz,2H),7.66(s,2H),7.52-7.36(m,3H),7.18(t,J=7.1Hz,2H),7.08(d,J=4.2Hz,1H),4.52(t,J=2.0Hz,2H),4.35-4.22(m,2H),3.86(s,3H),3.68(t,J=2.1Hz,1H)3.64–3.40(m,3H),,2.32–2.08(m,2H),1.88–1.64(m,2H),1.50–1.44(m,2H)MS:m/z(ESI+)620.8[M+H] + 。
Example 19.4- ((4- (4- (1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) butanoic acid
The synthesis of example 19 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in step 5, the intermediate 1- (phenyl) -2-oxopyrrolidine-3-carboxylic acid was used instead of 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ11.86(s,1H),8.70(d,J=7.2Hz,1H),8.48(t,J=6.8Hz,2H),7.62(s,2H),7.58-7.44(m,4H),7.36(t,J=6.8Hz,2H),7.22(d,J=3.2Hz,1H),4.42(t,J=1.7Hz,2H),4.34-4.38(m,2H),3.72(s,3H),3.64(t,J=2.1Hz,1H)3.60–3.44(m,3H),,1.93–1.76(m,2H),MS:m/z(ESI+)573.58,[M+H] + 。
Example 20.5- ((4- (4- (1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) pentanoic acid
The synthesis of example 20 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3, the intermediate raw material of 5-bromovalerate is used for replacing 4-bromobutyric acid methyl ester; in the 5 th reaction step, 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid was replaced with the intermediate 1-phenyl-2-oxopyrrolidine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ11.86(s,1H),8.70(d,J=7.2Hz,1H),8.48(t,J=6.8Hz,2H),7.62(s,2H),7.58-7.44(m,4H),7.36(t,J=6.8Hz,2H),7.22(d,J=3.2Hz,1H),4.42(t,J=1.7Hz,2H),4.34-4.38(m,2H),3.72(s,3H),3.64(t,J=2.1Hz,1H)3.60–3.44(m,3H),,1.93–1.76(m,2H),MS:m/z(ESI+)587.60[M+H] + 。
EXAMPLE 21.6- ((4- (4- (1- (4-fluorophenyl) -2-oxopyrrolidine-3-carboxamide) phenoxy) -6-methoxyquinolin-7-yl) oxy) hexanoic acid
The synthesis of example 21 was performed with reference to the synthesis method of example 1. In the step 1 reaction, 4-nitrophenol is used for replacing 2-fluoro-4-nitrophenol; in the step 3, the intermediate raw material methyl 6-bromohexanoate is used for replacing methyl 4-bromobutyrate; in the 5 th step, 1- (4-fluorophenyl) -2-oxo-1, 2-dihydropyridine-3-carboxylic acid was replaced with the intermediate 1-phenyl-2-oxopyrrolidine-3-carboxylic acid.
1 H NMR(400MHz,DMSO)δ11.72(s,1H),8.62(d,J=7.2Hz,1H),8.40(t,J=8.6Hz,2H),7.60(s,2H),7.44-7.32(m,4H),7.30(t,J=7.1Hz,2H),7.04(d,J=4.1Hz,1H),4.32(t,J=2.1Hz,2H),4.26-4.12(m,2H),3.76(s,3H),3.60(t,J=4.6Hz,1H)3.46–3.34(m,4H),2.38–2.26(m,2H),1.86–1.64(m,2H),1.52–1.38(m,2H)MS:m/z(ESI+)602.9[M+H] + 。
Evaluation of biological Activity of Compounds of examples
Inhibition of the biochemical Activity of AXL, KDR and CSF-1R kinases by the Compounds of the examples
The biochemical activity of three kinases AXL, KDR and CSF-1R was determined by phosphorylation of a fluorescein-labeled tyrosine kinase substrate.
Reagent: AXL, KDR and CSF-1R tyrosine kinase (available from Carna Inc.),KinEASE-TK kit and 96 microwell plates (from Cisbio), ATP (from Sigma), dithiothreitol (DTT) (from Sigma), manganese chloride and magnesium chloride (from Sigma), XL-184 (as positive control) (from Shanghai Han Xiang Biotechnology Co., ltd.), a full wavelength multifunctional microplate reader (TECAN->M1000)。
The method comprises the following steps:
according to the kit instructions, AXL, KDR, CSF-1R tyrosine kinase buffer (1×), catalytic substrate solution (5×,5 μm), ATP solution (500 μm) were prepared, and the reaction solution was stopped (4×). When in test, three kinases are respectively and independently carried out, 2 mu L of AXL or KDR or CSF-1R kinase solution is respectively added into the test holes of the three 96 micro-well plates, and two holes are repeatedly arranged at each concentration; control wells were added with 2 μl (1×) of kinase buffer solution as control. The assay wells and control wells were each filled with kinase buffer (4. Mu.L), substrate solution (2. Mu.L), ATP solution (2. Mu.L). The reaction mixtures were incubated at 37℃for 0min, 10min, 20min, 30min, 40min, 50min, 60min, respectively, and 10. Mu.L of stop reaction solution was added thereto, followed by further incubation for 1 hour. Detecting fluorescence signal intensities at 665nm and 620nm with a full-wavelength multifunctional enzyme-labeled instrument at 317nm as excitation light wavelength, and calculating concentration (IC) of the compound at 50% inhibition according to ratio of 665nm fluorescence signal intensity/620 nm fluorescence signal intensity 50 Values), the results are shown in table 1.AXL, KDR and CSF-1R excitationEnzyme activity inhibition rate calculation: percentage inhibition = (F DMSO control -F Sample of )/(F DMSO control -F Negative control ) X 100%, DMSO added value was used as solvent control, and kinase-free negative control.
TABLE 1 inhibition of the biochemical Activity of the AXL, KDR and CSF-1R kinases by the example compounds (IC 50 ,nM)
Experimental results:
the results in table 1 show that: the compounds of the examples significantly inhibit the biochemical activity of AXL, KDR and CSF-1R kinases.
Inhibiting effect of example Compounds on proliferation of human leukemia MOLM-13 and human gastric cancer MKN-45 cells
1. Tumor cells: the MOLM-13 acute leukemia cell strain resistant to vascular endothelial growth factor, and the human gastric cancer cell MKN-45 cells were obtained from the university of medical science, southern university of medical science center.
2. The method comprises the following steps: the antiproliferative activity of the compounds of the examples on MOLM-13 acute leukemia cell lines was determined by Luminometer luminescence.
3. Instrument: promega microplate detector (CellTiter-Glo Luminescent Cell Viability Assay, promega).
4. Reagents and kits: RPMI1640 medium, fetal calf serum, dimethyl sulfoxide, penicillin-streptomycin, cell Titer-Gio detection kit. Cell culture bottle, CO 2 Incubator, cell culture microplate (96 well plate).
5. Tumor cell culture: resuscitates MOLM-13 tumor cells frozen in liquid nitrogen, and cultures the cells in RPMI cell culture medium containing 10% fetal bovine serum and 10% penicillin-streptomycin; when the cells grow to an exponential growth phase, the culture medium is sucked by a pipetting gun to be gently blown andcollecting cells, and re-suspending the cells in a culture solution; inoculating 5000-10000 cells in each hole, and uniformly distributing the cells; cells were incubated at 37℃with 5% CO 2 The culture was continued for 72 hours in a saturated humidity carbon dioxide incubator.
6. Example compounds and activity assays: the compound of the example was dissolved in dimethyl sulfoxide to prepare 10 concentration gradients, and different concentrations of the compound were added to the test wells according to the experimental design for further incubation for 72h. After the completion of the incubation, the 96-well plate was taken out and left at room temperature for 30 minutes, followed by detection of CTG. mu.L of CTG was added to the microwells, mixed well for 2 minutes, and left at room temperature for 10 minutes. Detecting and recording luminous signal value by using a microplate luminometer to observe cell activity, and calculating IC 50 Values, results are shown in Table 2.
TABLE 2 inhibition of proliferation of human leukemia MOLM-13 and human gastric cancer MKN-45 by example compounds
/>
The results in table 2 show that: the compound of the embodiment can obviously inhibit the proliferation of human leukemia MOLM-13 cells and the proliferation of human gastric cancer MKN-45 cells.
Anti-tumor effect of the Compounds of examples on human leukemia MOLM-13 cells in vivo
1. Cell culture: human leukemia MOLM-13 cells were cultured in DMEM medium containing 10% fetal bovine serum, 100U/mL penicillin and 100. Mu.g/mL streptomycin, with the flask placed at 37deg.C and 5% CO 2 Culturing in a saturated humidity carbon dioxide incubator.
2. Experimental animals: BALB/C-nu mice were purchased from Guangdong Kangdong Biotechnology Co., ltd, 40, 28-34 days old. License number: SCXK (cantonese) 2020-0054, experiment unit use license number: SYXK (Guangdong) 2018-0131.5 mice were housed in a cage and animals were kept in SPF animal houses and used for tumor cell inoculation experiments after one week of examination.
Molm-13 cell nude mouse engraftment model: when the number of MOLM-13 cells reaches the exponential growth phase, lightly blowing off the agglomerated suspension cells by a liquid-transferring gun, collecting the suspension cells into a centrifuge tube, centrifuging at 1000r/min for 5min, collecting the cells at the bottom of the centrifuge tube, re-suspending the cells by a serum-free culture medium, and adjusting the cell concentration to 2X 10 7 /mL. Sucking the cell suspension with 1mL syringe, inoculating under the right anterior axilla of nude mice, inoculating 0.1mL each nude mice, and inoculating cell number 2×10 6 /only. After tumor cell inoculation, the tumor growth of the nude mice inoculation part is observed daily or periodically, the size of the tumor of each animal is measured by a vernier caliper, and when the tumor growth volume reaches 100mm 3 In the above cases, experiments may be optionally performed. Of 40 nude mice vaccinated with tumor cells, 30 met the inclusion criteria.
4. Experimental grouping and dosing: the experiment was randomly divided into 4 groups including a solvent control group, a positive compound control group and two dose groups of 2.5mg/kg and 5mg/kg of the compound of example. Compound 3 was dissolved in 50% PEG400 and 50% distilled water (the total amount of PEG400 administered daily to mice was controlled below 0.5%) and the drug administered once daily, 0.1mL each time, for 7 consecutive days. Animal weights were measured daily, tumor size was measured every two days, and changes in the mice' diet, drinking water, body weight, hair, etc. were observed.
5. Method for evaluating antitumor effect of compound: after the end of the administration, tumor-bearing mice were anesthetized, photographed as a whole, and tumors were removed and weighed (tumor weights are expressed as mean ± SD), and tumor inhibition rates were calculated.
Calculation of Tumor Volume (TV):
TV=1/2×a×b 2
wherein a is the long diameter of the tumor, and b is the short diameter of the tumor.
Calculation of tumor inhibition (Tumor Growth Inhibition, TGI):
5-2. Calculation of percent body weight change before and after dosing of nude mice:
BW is the Weight of nude mice (Body Weight), BW Last day For the body weight of nude mice at the end of the experiment, BW First day The weight of nude mice at the time of group administration was calculated.
5-3 experimental results
As shown in FIG. 1, the compound of example 3 showed very remarkable antitumor effect and fast onset of action after continuous gastric lavage administration for 7 days in MOLM-13 cell-transplanted tumor nude mice.
As shown in fig. 2, the weight change before and after administration was compared, and no decrease in animal weight was observed in the 2.5mg/kg administration group during the administration period; weight gain of the 5mg/kg dosing group showed low toxicity of the compound.
The other compounds of this application were tested in the same manner and the results were similar to those of example 3.
Claims (10)
1.A compound of formula (I), an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof:
wherein,
R 1 is C 1 -C 6 Alkyl, R 2 Is thatOr R is 2 Is C 1 -C 6 Alkyl, R 1 Is that
Y is selected from C 1 -C 10 Alkylene, C 1 -C 10 Alkylene amino group, C 1 -C 10 Alkylene oxide, C 1 -C 10 Halogenated alkylene, piperidylene, C 1 -C 10 Alkylene piperidinyl, piperazinyl or C 1 -C 10 An alkylene piperazinyl group;
G 1 and G 2 Are independently selected from hydrogen, deuterium, halogen, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl or C 1 -C 6 An alkoxy group;
w is selected from the following groups:
2. the compound of claim 1, wherein R 1 Is C 1 -C 3 Alkyl, R 2 Is that Or R is 2 Is C 1 -C 3 Alkyl, R 1 Is->
Y is selected from C 3 -C 6 Alkylene, C 3 -C 6 Alkylene amino group, C 3 -C 6 Alkylene oxide, C 3 -C 6 A halogenated alkylene group.
3. The compound of claim 2, wherein R 1 Is C 1 -C 3 Alkyl, R 2 Is that Y is selected from C 3 -C 5 Alkylene or C 3 -C 5 A halogenated alkylene group.
4. The compound of claim 1, wherein G 1 And G 2 Each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine or iodine.
5. The compound of claim 1, wherein W is selected from the group consisting of:
6. a compound according to any one of claims 1 to 5, wherein the compound is selected from:
7. a pharmaceutical composition comprising a compound of any one of claims 1-6, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated thereof, and a pharmaceutically acceptable excipient.
8. Use of a compound according to any one of claims 1-6, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated product thereof or a pharmaceutical composition according to claim 7 in the manufacture of a medicament for the prevention or treatment of a disease caused by tyrosine protein kinase abnormality;
preferably, the tyrosine protein kinase is selected from one or more of receptor tyrosine kinase (AXL), vascular endothelial growth factor receptor 2 (KDR) and colony stimulating factor-1receptor (CSF-1R);
preferably, the diseases caused by tyrosine protein kinase abnormality include solid tumors such as gastric cancer, lung cancer, breast cancer, hematological tumors, inflammatory diseases and autoimmune diseases.
9. Use of a compound of any one of claims 1-6, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated thereof or a pharmaceutical composition of claim 7 in the manufacture of a medicament for inhibiting a tyrosine protein kinase;
preferably, the tyrosine protein kinase is selected from one or more of receptor tyrosine kinase (AXL), vascular endothelial growth factor receptor 2 (KDR) and colony stimulating factor-1receptor (CSF-1R).
10. A method of preventing or treating a disease caused by an abnormality in tyrosine protein kinase comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-6, an isomer thereof, a pharmaceutically acceptable salt thereof or a deuterated thereof or a pharmaceutical composition of claim 7;
preferably, the tyrosine protein kinase is selected from one or more of receptor tyrosine kinase (AXL), vascular endothelial growth factor receptor 2 (KDR) and colony stimulating factor-1receptor (CSF-1R);
preferably, the diseases caused by tyrosine protein kinase abnormality include solid tumors such as gastric cancer, lung cancer, breast cancer, hematological tumors, inflammatory diseases and autoimmune diseases.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210751111.0A CN117362275A (en) | 2022-06-29 | 2022-06-29 | Tyrosine protein kinase inhibitor and application thereof |
PCT/CN2022/104421 WO2024000615A1 (en) | 2022-06-29 | 2022-07-07 | Protein tyrosine kinase inhibitor and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210751111.0A CN117362275A (en) | 2022-06-29 | 2022-06-29 | Tyrosine protein kinase inhibitor and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117362275A true CN117362275A (en) | 2024-01-09 |
Family
ID=89383922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210751111.0A Pending CN117362275A (en) | 2022-06-29 | 2022-06-29 | Tyrosine protein kinase inhibitor and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117362275A (en) |
WO (1) | WO2024000615A1 (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
US20080004273A1 (en) * | 2006-05-30 | 2008-01-03 | Stephane Raeppel | Inhibitors of protein tyrosine kinase activity |
US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
CN102086211B (en) * | 2009-12-08 | 2013-09-11 | 广东东阳光药业有限公司 | Aromatic heterocyclic compounds serving as protein kinase inhibitor |
CN104072480B (en) * | 2013-03-27 | 2016-12-28 | 沈阳药科大学 | Quinolines and its preparation method and application |
CN104211686A (en) * | 2013-06-03 | 2014-12-17 | 天津隆博基因药物科技有限公司 | Quinoline derivatives and treatment use thereof |
WO2019231942A1 (en) * | 2018-06-01 | 2019-12-05 | Rigel Pharmaceuticals, Inc. | Quinoline derivatives useful as tyrosine kinase inhibitors |
EP3845527A4 (en) * | 2018-08-27 | 2022-06-08 | Beijing Yuezhikangtai Biomedicines Co., Ltd. | Multi-substituted pyridone derivatives and medical use thereof |
JP2022551422A (en) * | 2019-09-26 | 2022-12-09 | エグゼリクシス, インコーポレイテッド | Pyridone compounds and methods of use in modulating protein kinases |
-
2022
- 2022-06-29 CN CN202210751111.0A patent/CN117362275A/en active Pending
- 2022-07-07 WO PCT/CN2022/104421 patent/WO2024000615A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024000615A1 (en) | 2024-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111647000B (en) | Pyrazine derivative and application thereof in inhibition of SHP2 | |
KR101843752B1 (en) | Quinazoline derivative and preparation method therefor | |
CN111205286B (en) | Nitrile methyl piperazine derivative as KRAS G12C mutant protein inhibitor and application thereof | |
RU2528408C2 (en) | Method for preparing dihydroindenamide compounds, pharmaceutical compositions containing these compounds and using them as protein kinase inhibitor | |
RU2720810C2 (en) | Salts of a quinazoline derivative and a method for production thereof | |
JP6755922B2 (en) | New compounds, their preparation and their use | |
CN104945401A (en) | IP compounds and their use in therapy | |
WO2008015794A1 (en) | Boronated quinazoline derivative | |
CN104203242A (en) | Substituted quinolines as Bruton's tyrosine kinases inhibitors | |
WO2012011840A1 (en) | Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same | |
EP3749646B1 (en) | Heteroaryl compounds as kinase inhibitor | |
CN113480543B (en) | 2,6, 8-polysubstituted imidazo [1,2-a ] pyrazine and synthetic method and application thereof | |
JP2015515995A (en) | Substituted aminoquinazolines useful as kinase inhibitors | |
CN115353508B (en) | 5-pyridine-1H-indazole compound, pharmaceutical composition and application | |
JP2014532063A (en) | Quinazoline derivatives as kinase inhibitors and methods of use thereof | |
CN107151233B (en) | Hydrazone-containing pyrimidine derivative and application thereof | |
JP2022528109A (en) | Quinoline-containing compounds, pharmaceutical compositions and their use | |
CN117362275A (en) | Tyrosine protein kinase inhibitor and application thereof | |
WO2019228330A1 (en) | Substituted benzo[d]imidazole compound and pharmaceutical composition thereof | |
CN113072550B (en) | High-selectivity fibroblast growth factor receptor inhibitor and application thereof | |
WO2014071824A1 (en) | 4-quinazolinamine heterocyclic compound and use thereof | |
CN109438279B (en) | Small molecule compound for overcoming EGFR drug-resistant mutation and preparation method and application thereof | |
CN107652275B (en) | Quinazoline derivative and preparation method and application thereof | |
CN114685496B (en) | Hydroxamic acid based HDAC6 inhibitor synthesis and uses thereof | |
CN115124511B (en) | Tacrine derivatives, preparation method thereof and application of tacrine derivatives as CDK2/9 inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |